Journal
ACTA NEUROPATHOLOGICA
Volume 144, Issue 5, Pages 843-859Publisher
SPRINGER
DOI: 10.1007/s00401-022-02469-6
Keywords
-
Categories
Funding
- Lund University
- Vetenskapsradet [2019-0633]
- Instituto de Salud Carlos III [20/00448]
- Union [PI18/01556, PI21/00914]
- Consejeria de Economia, Innovacion, Ciencia y Empleo, Junta de Andalucia [P18-RT-1372]
- Kungliga Fysiografiska Sallskapet i Lund [20191114ABS, 20211129ABS]
- Greta och Johan Kocks stiftelser [20201201ABS]
- Consejeria de Economia, Conocimiento, E mpresas y Universidad, Junta de Andalucia [US-1264806]
- Ministerio de Ciencia, Innovacion y Universidades [RTI2018-098645-B-100, PID2021-124096OB-100]
Ask authors/readers for more resources
Galectin-3 is a crucial player in microglial activation in Alzheimer's disease, with increased levels observed in AD patients and association with tau inclusions. It clusters with other neuroinflammatory markers in cerebrospinal fluid and may serve as a potential target for AD-modifying therapies.
Galectin-3 (Gal-3) is a beta-galactosidase binding protein involved in microglial activation in the central nervous system (CNS). We previously demonstrated the crucial deleterious role of Gal-3 in microglial activation in Alzheimer's disease (AD). Under AD conditions, Gal-3 is primarily expressed by microglial cells clustered around A beta plaques in both human and mouse brain, and knocking out Gal-3 reduces AD pathology in AD-model mice. To further unravel the importance of Gal-3-associated inflammation in AD, we aimed to investigate the Gal-3 inflammatory response in the AD continuum. First, we measured Gal-3 levels in neocortical and hippocampal tissue from early-onset AD patients, including genetic and sporadic cases. We found that Gal-3 levels were significantly higher in both cortex and hippocampus in AD subjects. Immunohistochemistry revealed that Gal-3+ microglial cells were associated with amyloid plaques of a larger size and more irregular shape and with neurons containing tau-inclusions. We then analyzed the levels of Gal-3 in cerebrospinal fluid (CSF) from AD patients (n=119) compared to control individuals (n= 36). CSF Gal-3 levels were elevated in AD patients compared to controls and more strongly correlated with tau (p-Tau181 and t-tau) and synaptic markers (GAP-43 and neurogranin) than with amyloid-beta. Lastly, principal component analysis (PCA) of AD biomarkers revealed that CSF Gal-3 clustered and associated with other CSF neuroinflammatory markers, including sTREM-2, GFAP, and YKL-40. This neuroinflammatory component was more highly expressed in the CSF from amyloid-beta positive (A+), CSF p-Tau181 positive (T+), and biomarker neurodegeneration positive/negative (N+/-) (A + T +N+/-) groups compared to the A + T-N- group. Overall, Gal-3 stands out as a key pathological biomarker of AD pathology that is measurable in CSF and, therefore, a potential target for disease-modifying therapies involving the neuroinflammatory response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available